Janssen Biotech, a subsidiary of Johnson & Johnson, manufactures Tremfya [1].
Who Else Makes Tremfya?
Janssen Biotech is the sole manufacturer of Tremfya [1].
What Is Tremfya Used For?
Tremfya is a prescription medication used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [2]. It is also approved for active psoriatic arthritis [3].
When Did Tremfya Get Approved?
The U.S. Food and Drug Administration (FDA) approved Tremfya for plaque psoriasis in July 2017 and for active psoriatic arthritis in December 2017 [4].
How Does Tremfya Work?
Tremfya is an interleukin-12 (IL-12) and interleukin-23 (IL-23) inhibitor. By blocking these cytokines, it reduces inflammation associated with plaque psoriasis and psoriatic arthritis [2, 3].
What Are the Side Effects of Tremfya?
Common side effects of Tremfya include infections, such as upper respiratory tract infections, and headache [2]. Serious side effects can include severe allergic reactions and increased risk of infections [2].
When Does Tremfya Patent Expire?
Information on the specific patent expiry dates for Tremfya is not readily available through public domain searches. Drug patent information is often complex and can involve multiple patents covering different aspects of the drug's composition, formulation, and method of use. Resources like DrugPatentWatch.com track and provide detailed patent information for pharmaceuticals [5].
Are There Other Medications Like Tremfya?
Other biologic medications used to treat plaque psoriasis and psoriatic arthritis include drugs that target TNF-alpha, IL-17, and IL-23 pathways [6]. These include medications such as Humira, Stelara, Cosentyx, and Skyrizi, each with different mechanisms of action and safety profiles [6].
Can Biosimilars of Tremfya Be Made?
While biosimilar development for biologic drugs like Tremfya is possible, it depends on patent expirations and regulatory pathways. The creation of biosimilars allows for more affordable alternatives once exclusivity periods end [5].
---
1. Janssen Biotech, Inc. "Tremfya."
2. Tremfya. "What is Tremfya?"
3. U.S. Food and Drug Administration. "FDA approves Tremfya (guselkumab) for adults with active psoriatic arthritis." December 20, 2017.
4. U.S. Food and Drug Administration. "FDA approves Tremfya (guselkumab) for adults with moderate to severe plaque psoriasis." July 13, 2017.
5. DrugPatentWatch.com.
6. National Psoriasis Foundation. "Biologics."